What is the recommended steroid tapering (de‑escalation) protocol for eosinophilic granulomatosis with polyangiitis (EGPA) after achieving clinical remission?

Steroid De-escalation Protocol for EGPA

After achieving remission in EGPA, taper prednisone to ≤7.5 mg/day (or ideally ≤4 mg/day) as the target maintenance dose, with the goal of complete discontinuation when using mepolizumab or other biologics. 1

Defining Remission Before Tapering

Before initiating steroid de-escalation, confirm remission is achieved:

• Birmingham Vasculitis Activity Score (BVAS) = 0
• No clinical signs or symptoms of active vasculitis
• Asthma and ENT manifestations controlled
• Maximum prednisone dose of 7.5 mg/day (traditional threshold) or 4 mg/day (more stringent, preferred with biologics) 1

Steroid Tapering Timeline and Approach

With Mepolizumab (Anti-IL-5 Biologic)

The most recent high-quality evidence demonstrates that aggressive steroid tapering after mepolizumab initiation is both safe and effective:

• Median time to complete GC discontinuation: 452 days (~15 months) from mepolizumab initiation 2
• 86% of patients achieved complete steroid discontinuation during follow-up 2
• 55% achieved early GC-free status within 500 days 2

Key findings supporting accelerated tapering:

• More recent treatment protocols (faster tapering) were associated with shorter GC duration without increased organ damage (Vasculitis Damage Index increased in only 11% of patients) 2
• Higher eosinophil counts at mepolizumab initiation predicted successful GC discontinuation 2
• Complete steroid discontinuation was achieved in 57% (8/14) of patients in real-world practice 3

Practical Tapering Strategy

Based on the evidence, implement this approach:

1. Initiate mepolizumab (300 mg monthly for EGPA; note: even 100 mg monthly showed efficacy in small studies 4)

2. Begin tapering after clinical response (typically within first 1-3 months of biologic therapy)

3. Target timeline: Aim for GC discontinuation within 12-18 months of mepolizumab initiation, based on the median 452-day discontinuation time 2

4. Taper rate: While specific mg/week reductions aren't detailed in the guidelines, the evidence shows that accelerated tapering after biologic initiation is safe and associated with better outcomes 2

Without Biologics (Traditional Approach)

For patients not receiving biologics:

• Target maintenance dose: ≤7.5 mg/day prednisone 1
• Vasculitis relapses occur most frequently in the first 2 years (48% at 5 years) 5
• Isolated asthma/rhinosinus exacerbations continue throughout follow-up (56% at 5 years) 5
• Traditional immunosuppressants (azathioprine) showed no long-term benefit in preventing relapses or reducing cumulative GC use in non-severe EGPA 5

Critical Pitfalls to Avoid

Do not accept long-term moderate-dose steroids as adequate remission:

• The paradigm has shifted—even low-dose GCs (>4-7.5 mg/day) carry substantial morbidity 6
• Complete GC discontinuation should be the goal when biologics are available 2, 3

Monitor for two distinct types of flares:

• Vasculitis relapses (peak in first 2 years, require treatment intensification)
• Isolated asthma/rhinosinus exacerbations (occur throughout follow-up, may not represent true vasculitis relapse) 5

Timing of biologic initiation:

• Earlier mepolizumab initiation (shorter interval from GC initiation) was associated with faster GC discontinuation in recent practice patterns 2
• Consider biologics early rather than prolonging steroid exposure

Alternative Approaches for Severe/Refractory Cases

For patients unable to taper steroids or with contraindications to escalation:

• Rituximab can achieve sustained remission without prednisolone escalation, with successful tapering from 17.5 mg to 1 mg over 2 years documented 7
• Particularly useful in perioperative settings or when GC escalation is unsafe 7